Concert Pharmaceuticals (NASDAQ:CNCE) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.85) by $0.13, Fidelity Earnings reports. Concert Pharmaceuticals had a negative net margin of 7,303.34% and a negative return on equity of 49.44%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.35 million.
NASDAQ:CNCE traded up $0.33 during mid-day trading on Friday, hitting $6.73. The stock had a trading volume of 303,600 shares, compared to its average volume of 223,753. The company has a 50 day simple moving average of $6.77 and a 200-day simple moving average of $9.76. The stock has a market capitalization of $152.32 million, a price-to-earnings ratio of -2.80 and a beta of 0.88. The company has a current ratio of 19.63, a quick ratio of 19.63 and a debt-to-equity ratio of 0.12. Concert Pharmaceuticals has a 52 week low of $5.36 and a 52 week high of $17.83.
In other Concert Pharmaceuticals news, Director Heek Christi Van acquired 5,000 shares of the stock in a transaction dated Tuesday, October 8th. The shares were bought at an average price of $5.90 per share, with a total value of $29,500.00. Following the purchase, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $29,500. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 11.00% of the company’s stock.
A number of research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. SunTrust Banks reduced their price target on shares of Concert Pharmaceuticals from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, September 30th. HC Wainwright reduced their price target on shares of Concert Pharmaceuticals from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Zacks Investment Research downgraded shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Stifel Nicolaus downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $18.00 to $8.00 in a research report on Friday, September 27th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $15.63.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.